Oasmia Release: Positive Phase III Result From the Interim Analysis of the Study in Ovarian Cancer With Paclical(R)
8/2/2011 10:00:57 AM
UPPSALA, Sweden, Aug. 2, 2011 (GLOBE NEWSWIRE) -- Oasmia has completed an interim analysis of the ongoing Phase III study in ovarian cancer. The interim analysis, based on data from approximately 400 patients, showed the expected efficacy of Paclical® compared to the comparator, Taxol®. The results pointed towards a favorable efficacy for Paclical®. Based on these results, Oasmia will apply for marketing authorization for Paclical® within the European Union and some countries within the emerging markets, for the indication ovarian cancer.